Tempus AI (TEM) is back in focus after reporting 36.1% year-over-year revenue growth in Q1 2026 and lifting its full-year revenue guidance, supported by oncology diagnostics, data applications, and new pharmaceutical collaborations.

Despite the strong Q1 update and new collaborations in oncology and Alzheimer’s care, Tempus AI’s short-term sentiment has been weak. The company reported a 1-day share price return of 7.61% and a year-to-date share price return of 20.74% against a 1-year total shareholder return of 24.21%. This suggests that momentum has faded after an earlier rebound.

If you are looking beyond Tempus AI to see where else AI in healthcare is gaining traction, this is a good moment to scan 35 healthcare AI stocks.

With Tempus AI shares down roughly 21% year to date and trading at what some analysts view as a discount to their targets, you have to ask: Is there still upside here, or is the market already pricing in future growth?

Most Popular Narrative: 31.7% Undervalued

Tempus AI’s most followed narrative pegs fair value at $72.40 per share, compared with a last close of $49.43, and frames that gap around data scale and partnerships.

Tempus AI's large-scale partnerships with biopharma (e.g., AstraZeneca Pathos foundation model) demonstrate rising demand for AI-driven insights amid growing healthcare data complexity, likely driving recurring data licensing revenue and supporting overall earnings stability.

Want to see what kind of revenue runway those partnerships are assumed to support, and how margins are expected to shift as the model scales? The full narrative connects those moving parts to that $72.40 figure.

Result: Fair Value of $72.40 (UNDERVALUED)

However, investors still need to watch for tougher genomics and AI competition, as well as any delays or uncertainty around reimbursement that could pressure margins and data monetization.

Another View: What P/S Says About Tempus AI

The narrative around Tempus AI leans on a fair value of $72.40 per share, but the P/S ratio tells a more cautious story. The stock trades on a P/S of 6.5x, compared with about 4x for peers and 3.5x for the wider US Life Sciences industry, and only slightly below a fair ratio of 6.8x.

In plain terms, the market is already paying a premium for each dollar of Tempus AI revenue, so any slip in growth or data monetization could matter more than the DCF style upside suggests. That leaves you asking which signal you trust most.

Next Steps

Mixed signals so far, with upside potential and clear pressure points, mean this story is far from settled, so act quickly, study the data for yourself, and weigh both the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Tempus AI has sharpened your thinking, do not stop here. The real edge comes from comparing it with a focused set of other high quality opportunities.

• Target strong fundamentals and financial resilience by scanning the solid balance sheet and fundamentals stocks screener (44 results).
• Hunt for quality at a marked discount by reviewing the screener containing 23 high quality undiscovered gems.
• Prioritise stability and capital protection by checking the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.